Quantum-Si Reports Third Quarter 2024 Financial Results

Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si,” "QSI” or the "Company”), The Protein Sequencing Company™, today announced financial results for the third quarter ended September 30, 2024.

Press Release Highlights

• Reported revenue of $787,000 for the third quarter of 2024
• Announced that Liberate Bio has integrated Platinum^® Next-Generation Sequencing into their platform for developing novel gene therapies with improved targeting capabilities
• Announced appointments of industry veteran Todd Bennett as Chief Commercial Officer ("CCO”), John Vieceli, Ph.D. as Chief Product Officer and Lindsay Thompson as Chief Human Resources Officer
• Highlighted Platinum-based advances in proteomic analysis presented at Human Proteome Organization World Congress 2024 in Dresden, Germany
• Highlighted a manuscript from researchers at the University of Virginia published on BioRxiv highlighting Platinum’s capability to discriminate peptide variants at single amino acid resolution
• New library preparation kit and barcoding kit remain on track for launch before year end
• Highlighted the Company’s upcoming Investor Day on Wednesday, November 20, 2024, beginning at 10:00 a.m. ET

"We are pleased to see continued adoption of Platinum across multiple market segments, including academic research, pharma/biotech and most recently, adoption by our first customer from the contract research organization market. Under the leadership of our new CCO, there has been clear improvement in commercial execution and the overall acceleration of our sales pipeline,” said Jeff Hawkins, President and Chief Executive Officer of Quantum-Si. "Even with this acceleration, we, like others in the tools space, have observed some lengthening of the sales cycle in the third quarter, making it likely that we will not achieve our full year guided revenue range of $3.7 million to $4.2 million. We have clear strategies in place that we believe will allow us to get as close to the guidance range as possible and despite the potential short fall, we remain very confident in the long-term commercial opportunity for Platinum and the growth of the proteomics market in general. We are excited for the future and believe that we will continue to deliver solid quarter over quarter growth as we move forward.”

Hawkins continued, "In addition, we continue to execute on our innovation roadmap and are on track to deliver two new kits by end of the year, which we believe will continue to drive broader market adoption. We are looking forward to revealing more details on our exciting technology roadmap and expanding commercial opportunities at our upcoming Investor Day on November 20th.”

Third Quarter 2024 Financial Results

For the third quarter of 2024, the Company recorded revenue of $787,000. Gross profit was $367,000 and gross margin was 47%. For the nine months ended September 30, 2024, the Company recorded revenue of $1.9 million, gross profit of $990,000, and gross margin of 53%. The periodic gross margin rate is expected to be variable in the near term as the Company works through the initial stages of commercialization as well as the timing and mix of product sales between instruments and consumable kits.

Total operating expenses were $28.5 million in the third quarter of 2024, compared to $27.3 million for the same period in the prior year, and $78.9 million for the nine months ended September 30, 2024, compared to $83.6 million for the same period in the prior year. Adjusted total operating expenses were $26.0 million in the third quarter of 2024 compared to $23.9 million for the same period in the prior year, and adjusted total operating expenses for the nine months ended September 30, 2024 were $72.3 million compared to $72.6 million for the same period in the prior year. The Company has successfully reduced overall adjusted operating expenses on a year to date basis while funding the ramp up in commercialization efforts. This reduction was driven by the Company’s 2023 R&D realignment initiative to streamline and focus R&D efforts on delivering product enhancements to customers. Overall, the Company has been able to reduce core areas of spend while accelerating R&D focus, efficiency, and delivery while still funding the Company’s full commercial launch of its Platinum^® instrument.

Net loss was $25.3 million in the third quarter of 2024, compared to a net loss of $24.7 million in the same period of the prior year, and a net loss of $67.9 million for the nine months ended September 30, 2024, compared to a net loss of $73.9 million for the same period in the prior year. Adjusted EBITDA was negative $24.5 million in the third quarter of 2024, compared to negative $22.6 million in the same period of the prior year, and negative $67.7 million for the nine months ended September 30, 2024, compared to negative $69.2 million for the same period in the prior year. A reconciliation of the non-GAAP financial measures adjusted total operating expenses and adjusted EBITDA is provided in a table included in this press release.

As of September 30, 2024, the Company’s cash and cash equivalents and investments in marketable securities were $196.3 million.

Financial Guidance

The Company provided updated full year 2024 financial guidance for adjusted operating expenses and cash usage as follows:

The Company also updated its expectation that the balance in cash and cash equivalents and investments in marketable securities of $196.3 million as of September 30, 2024 will provide a runway into the second half of 2026.

Webcast and Conference Call Information

Quantum-Si will host a conference call to discuss its third quarter 2024 financial results on Tuesday, November 12, 2024, at 8:00 a.m. Eastern Time. Individuals interested in listening to the conference call may do so by joining the live webcast in the Investors section of the Quantum-Si website under Events & Presentations. Alternatively, individuals can register here to receive a dial-in number and personalized PIN to participate in the call. An archived webcast of the event will be available for replay following the event.

Investor Day

The Company will host an Investor Day on Wednesday, November 20^th beginning at 10:00 a.m. ET. To access the event, a live audio webcast will be available on the Investors section of the Company’s website.

About Quantum-Si Incorporated

Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company’s Platinum^® instrument enables Next-Generation Protein Sequencing™ that advances proteomic research, drug discovery, and diagnostics beyond what has been possible with existing proteomic tools. Learn more at quantum-si.com or follow us on LinkedIn or X.

Use of Non-GAAP Financial Measures

This press release presents the non-GAAP financial measures "adjusted total operating expenses” and "adjusted EBITDA.” The most directly comparable measures for these non-GAAP financial measures are total operating expenses and net loss. The Company has included below adjusted total operating expenses, which presents the Company’s total operating expenses after excluding goodwill impairment, stock-based compensation and restructuring costs. In addition, adjusted EBITDA further excludes interest, taxes, depreciation, amortization, dividend income, unrealized and realized gains and losses on marketable securities, changes in fair value of warrant liabilities and other income or expense.

A discussion of the reasons why management believes that the presentation of non-GAAP financial measures provides useful information to investors regarding the Company’s financial condition and results of operations is included as Exhibit 99.2 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission (the "SEC”) on November 12, 2024.

Forward Looking Statements

This press release includes "forward-looking statements” within the meaning of the "safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect,” "estimate,” "project,” "budget,” "forecast,” "anticipate,” "intend,” "plan,” "may,” "will,” "could,” "should,” "believes,” "predicts,” "potential,” "continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s expectations with respect to future performance and development and commercialization of products and services, its anticipated cash runway and its financial guidance for the full year 2024. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the inability to maintain the listing of the Company’s Class A common stock on The Nasdaq Stock Market; the ability of the Company to grow and manage growth profitably and retain its key employees; the Company’s ongoing leadership transitions; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company’s product development and commercialization activities; the commercialization and adoption of the Company’s existing products and the success of any product the Company may offer in the future; the potential attributes and benefits of the Company’s commercialized Platinum^® protein sequencing instrument and kits and the Company’s other products once commercialized; the Company’s ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company’s ability to identify, in-license or acquire additional technology; the Company’s ability to maintain its existing lease, license, manufacture and supply agreements; the Company’s ability to compete with other companies currently marketing or engaged in the development or commercialization of products and services that serve customers engaged in proteomic analysis, many of which have greater financial and marketing resources than the Company; the size and growth potential of the markets for the Company’s products and services, and its ability to serve those markets once commercialized, either alone or in partnership with others; the Company’s estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company’s financial performance; and other risks and uncertainties described under "Risk Factors” in the Company’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and in the Company’s other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241112920059/en/